StockData
AstraZeneca PLC logo

AstraZeneca PLC

AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)

Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%

AstraZeneca Fasenra (benralizumab) — Worldwide product sales by Quarter

Fasenra (benralizumab) — Worldwide product sales ($M) ($M)

QuarterlyAnnual

AstraZeneca Fasenra (benralizumab) — Worldwide product sales: $570M in Q2 2026, up 13.5% from a year earlier. That is the highest of the 34 quarters on record here.

Latest, Q2 2026
570
Period ended Jun 30, 2026
Change on a year earlier
+13.5%
502 in Q2 2025
History
34 quarters
Since Q1 2018
Sources
27
Documents cited below

Where the Q2 2026 figure comes from

“|| Fasenra | 570 | | 14 | | 13 | | 338 | | 10 | | 46 | | 81 | | 75 | | 129 | | 3 | | ( 1 ) | | 57 | | 29 | | 34”

Source: Form 6-K FY2026Q2 Earnings Release ↗

Reported in Form 6-K Quarterly & Form 20-F Product Sales by Medicine & Region Tables.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedFasenra (benralizumab) — Worldwide product sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026570+13.5%Form 6-K FY2026Q2 Earnings Release ↗
Q1 2026Mar 31, 2026483+15.6%Form 6-K FY2026Q1 Earnings Release ↗
Q4 2025Dec 31, 2025530+12.5%Form 6-K FY2025Q4 Earnings Release ↗
Q3 2025Sep 30, 2025530+21.6%Form 6-K FY2025Q3 Earnings Release ↗
Q2 2025Jun 30, 2025502+18.7%Form 6-K FY2025Q2 Earnings Release ↗
Q1 2025Mar 31, 2025418+16.8%Form 6-K FY2025Q1 Earnings Release ↗
Q4 2024Dec 31, 2024471+12.1%Form 6-K FY2024Q4 Earnings Release ↗
Q3 2024Sep 30, 2024436+12.1%Form 6-K FY2024Q3 Earnings Release ↗
Q2 2024Jun 30, 2024423+4.2%Form 6-K FY2024Q2 Earnings Release ↗
Q1 2024Mar 31, 2024358+5.9%Form 6-K FY2024Q1 Earnings Release ↗
Q4 2023Dec 31, 2023420+10.2%Form 6-K FY2023Q4 Earnings Release ↗
Q3 2023Sep 30, 2023389+10.2%Form 6-K FY2023Q3 Earnings Release ↗
Q2 2023Jun 30, 2023406+14.7%Form 6-K FY2023Q2 Earnings Release ↗
Q1 2023Mar 31, 2023338+9.7%Form 6-K FY2023Q1 Earnings Release ↗
Q4 2022Dec 31, 2022381+6.7%Form 6-K FY2022Q4 Earnings Release ↗
Q3 2022Sep 30, 2022353+9.6%Form 6-K FY2022Q3 Earnings Release ↗

Breakdown

What makes up fasenra (benralizumab) — Worldwide product sales

Cite this data

StockData. (2026). AstraZeneca Fasenra (benralizumab) — Worldwide product sales ($M), quarterly Q1 2018–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-fasenra-world

See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.